Underwriters Exercise Over-allotment Option on Thermo Fisher's $2.2B Public Offering | GenomeWeb

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific today said that the underwriters of its recently announced $2.2 billion public offering of common stock have exercised their over-allotment option.

The underwriters purchased nearly 3.9 million additional shares of Thermo Fisher's stock at $85.50 per share in exercising the over-allotment option.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.

In Science this week: new chromatin imaging approach, and more.